Summary
Latest filing:
ARCH Venture Fund X, L.P. is 10% Owner of Aspen Neuroscience, Inc. (ASPE). 1 SEC Form 4 filing on record, dated 3 November 2026. Most recent open-market trade: bought $18.00M of ASPE on 3 November 2026. Lifetime open-market purchases: $20.00M.
Recent transactions
12The latest 12 SEC Form 4 transactions reported by ARCH Venture Fund X, L.P..
Trading pattern
InsiderAlpha's records for ARCH Venture Fund X, L.P. go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. The typical open-market purchase is $6.67M (3 buys totaling $20.00M). The largest single buy on record is $18.00M of ASPE in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies ARCH Venture Fund X, L.P. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Partners XIV, L.P. - $18.00M in ASPE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is ARCH Venture Fund X, L.P.?
ARCH Venture Fund X, L.P. is an investment firm, tracked as 10% Owner of Aspen Neuroscience, Inc. (ASPE). InsiderAlpha holds 1 primary Form 4 filing for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has ARCH Venture Fund X, L.P. submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has ARCH Venture Fund X, L.P. been buying or selling stock?
Recorded transactions: 3 open-market purchases ($20.00M) and 0 open-market sales across all tracked filings.